WO2001062207A3 - Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation - Google Patents
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation Download PDFInfo
- Publication number
- WO2001062207A3 WO2001062207A3 PCT/US2001/006034 US0106034W WO0162207A3 WO 2001062207 A3 WO2001062207 A3 WO 2001062207A3 US 0106034 W US0106034 W US 0106034W WO 0162207 A3 WO0162207 A3 WO 0162207A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastrointestinal inflammation
- inflammatory bowel
- bowel disease
- forms
- treating inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002399550A CA2399550A1 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
AU2001241751A AU2001241751B2 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
IL15134501A IL151345A0 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
AU4175101A AU4175101A (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
EP01913036A EP1259264A4 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
AU2005237172A AU2005237172A1 (en) | 2000-02-23 | 2005-11-25 | Method for Treating Inflammatory Bowel Disease and Other Forms of Gastrointestinal Inflammation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18425600P | 2000-02-23 | 2000-02-23 | |
US60/184,256 | 2000-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001062207A2 WO2001062207A2 (en) | 2001-08-30 |
WO2001062207A3 true WO2001062207A3 (en) | 2001-12-20 |
Family
ID=22676177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/006034 WO2001062207A2 (en) | 2000-02-23 | 2001-02-22 | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
Country Status (6)
Country | Link |
---|---|
US (2) | US6613751B2 (en) |
EP (1) | EP1259264A4 (en) |
AU (3) | AU4175101A (en) |
CA (1) | CA2399550A1 (en) |
IL (1) | IL151345A0 (en) |
WO (1) | WO2001062207A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
JP4359654B2 (en) * | 1996-01-30 | 2009-11-04 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Gene expression vector for generating antigen-specific immune response and method of use thereof |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DE69932717T2 (en) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1204425B1 (en) | 1999-08-19 | 2009-01-07 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP1322655B1 (en) * | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020098199A1 (en) * | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020107212A1 (en) * | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
AU2001275294A1 (en) * | 2000-06-07 | 2001-12-17 | Biosynexus Incorporated. | Immunostimulatory RNA/DNA hybrid molecules |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
US7354909B2 (en) | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
AU2002363182A1 (en) * | 2001-11-02 | 2003-05-12 | Ribopharma Ag | Smad7 inhibitors for the treatment of cns diseases |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
DE60239566D1 (en) * | 2002-06-14 | 2011-05-05 | Brigham And Women S Hospital Boston | PROCESS FOR TREATMENT AND PREVENTION OF KOLITIS IN WHICH IL-13 AND NK-T CELLS ARE INVOLVED |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
NZ538628A (en) | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
MXPA05004588A (en) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection. |
JP4976653B2 (en) * | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides |
AU2003300919A1 (en) * | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
CN100546998C (en) * | 2002-12-23 | 2009-10-07 | 戴纳伐克斯技术股份有限公司 | Immunostimulatory sequence oligonucleotides and using method |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
ITRM20030149A1 (en) | 2003-04-02 | 2004-10-03 | Giuliani Spa | ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD |
CA2540949A1 (en) | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
AU2005213305A1 (en) * | 2004-02-03 | 2005-08-25 | Daniel Rachmilewitz | Methods of treating irritable bowel syndrome |
CA2598831A1 (en) | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
NZ561144A (en) * | 2005-03-04 | 2009-09-25 | Dynavax Tech Corp | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
EP1877074B1 (en) | 2005-04-15 | 2013-03-27 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells |
CA2637833A1 (en) * | 2006-01-20 | 2007-07-26 | Morinaga Milk Industry Co., Ltd | Pharmaceutical composition, food or drink, or feed for intestinal disease |
NZ571965A (en) * | 2006-03-30 | 2012-02-24 | Engene Inc | Chitosan-based nanoparticles and methods for transfecting gut cells in vivo |
EP2139462B1 (en) * | 2007-03-30 | 2014-01-22 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
US8188058B2 (en) * | 2007-04-19 | 2012-05-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
KR20100068422A (en) * | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | Immune stimulatory oligonucleotide analogs containing modified sugar moieties |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
AR091569A1 (en) | 2012-06-28 | 2015-02-11 | Intervet Int Bv | TOLL TYPE RECEIVERS |
US9562066B2 (en) | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
WO2016083315A1 (en) * | 2014-11-24 | 2016-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases |
MA41271A (en) * | 2014-12-26 | 2017-10-31 | Celgene Alpine Invest Company Ii Llc | METHODS OF USE OF OLIGONUCLEOTIDES ANTISENS TARGETING SMAD7 |
US20200281950A1 (en) * | 2015-12-28 | 2020-09-10 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6194388B1 (en) * | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6228371B1 (en) * | 1995-06-15 | 2001-05-08 | University Of Victoria Innovation And Development Corp. | Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
WO1999051259A2 (en) | 1998-04-03 | 1999-10-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20030013668A1 (en) * | 1998-07-07 | 2003-01-16 | Dange Veerapanane Ph.D | Antisense oligonucleotides targeted to il-15 |
AP2006003503A0 (en) | 1999-09-25 | 2006-02-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
EP1220684B2 (en) | 1999-09-27 | 2010-07-14 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
-
2001
- 2001-02-22 US US09/791,500 patent/US6613751B2/en not_active Expired - Fee Related
- 2001-02-22 EP EP01913036A patent/EP1259264A4/en not_active Withdrawn
- 2001-02-22 CA CA002399550A patent/CA2399550A1/en not_active Abandoned
- 2001-02-22 WO PCT/US2001/006034 patent/WO2001062207A2/en active IP Right Grant
- 2001-02-22 AU AU4175101A patent/AU4175101A/en active Pending
- 2001-02-22 IL IL15134501A patent/IL151345A0/en unknown
- 2001-02-22 AU AU2001241751A patent/AU2001241751B2/en not_active Ceased
-
2003
- 2003-04-11 US US10/412,151 patent/US7485627B2/en not_active Expired - Fee Related
-
2005
- 2005-11-25 AU AU2005237172A patent/AU2005237172A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194388B1 (en) * | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6228371B1 (en) * | 1995-06-15 | 2001-05-08 | University Of Victoria Innovation And Development Corp. | Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
Also Published As
Publication number | Publication date |
---|---|
AU2001241751B2 (en) | 2005-09-01 |
AU2005237172A1 (en) | 2005-12-15 |
EP1259264A2 (en) | 2002-11-27 |
WO2001062207A2 (en) | 2001-08-30 |
US6613751B2 (en) | 2003-09-02 |
IL151345A0 (en) | 2003-04-10 |
US20020042387A1 (en) | 2002-04-11 |
EP1259264A4 (en) | 2005-08-31 |
US20030176389A1 (en) | 2003-09-18 |
AU4175101A (en) | 2001-09-03 |
US7485627B2 (en) | 2009-02-03 |
CA2399550A1 (en) | 2001-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001062207A3 (en) | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation | |
AU2001269742A1 (en) | Method of treating gastrointestinal diseases associated with species of genus clostridium | |
WO2003045228A3 (en) | Methods for treating autoimmune disorders, and reagents related thereto | |
WO2001092308A3 (en) | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof | |
AU2001259795A1 (en) | Technique for securely conducting online transactions | |
AU2001249172A1 (en) | Stress-induced interposed connector | |
WO2005044199A3 (en) | Combination of proton pump inhibitor and sleep aid | |
WO2001075178A3 (en) | Methods for identifying peptide aptamers capable of altering a cell phenotype | |
WO2004006834A3 (en) | Leflunomide analogs for treating rheumatoid arthritis | |
WO2001072822A3 (en) | Genes involved in intestinal inflammatory diseases and use thereof | |
MXPA03002861A (en) | Retinoids for the treatment of emphysema. | |
WO2003102012A3 (en) | New etonogestrel esters | |
AU2001264172A1 (en) | Methods and compositions for diagnosing chronic immune disease | |
WO1999059617A3 (en) | Immunoregulator | |
WO2004058158A3 (en) | Treatment of metastatic cancer with the b-subunit of shiga toxin | |
AU2001251223A1 (en) | Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer | |
WO2002039122A3 (en) | Methods for the identification and the treatment of cardiovascular disease | |
WO2004026228A3 (en) | Method for reducing morbidity and mortality in critically ill patients | |
WO2003050137A3 (en) | Toll-like receptor 4 mutations | |
MXPA03001506A (en) | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases. | |
AU2001251507A1 (en) | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death | |
AU2003288969A8 (en) | System and method for conducting residential financing transactions | |
GB0030804D0 (en) | Method of conducting transactions | |
ZA200206252B (en) | Method and compositions for treating an inflammatory disease. | |
WO2004078180A3 (en) | Naaladase inhibitors for treating opioid tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151345 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2399550 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001241751 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001913036 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001913036 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001241751 Country of ref document: AU |